News

Alyftrek, triple-combination CF treatment, approved in UK

The U.K. Medicines and Healthcare Products Regulatory Agency approved Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor) as a cystic fibrosis (CF) treatment for patients ages 6 and older. The triple-combination CFTR modulator, developed by Vertex Pharmaceuticals, is indicated for patients who have at least one copy of a responsive…

Kaftrio eases some CF symptoms after lung transplant: Study

Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor that’s marketed as Trikafta in the U.S., may ease breathing and digestive symptoms in adults with cystic fibrosis (CF) who’ve had a lung transplant, a study from the Netherlands suggests. Researchers did observe a slight, but significant, increase in creatinine,…

Biomx raises $12M to advance phage therapy for CF infections

Biomx has raised $12 million in financing to advance BX004, a phage therapy being developed to treat bacterial infections — specifically, ones caused by Pseudomonas aeruginosa, known as P. aeruginosa for short — in people with cystic fibrosis (CF). The funding comes from investors purchasing the company’s stock,…

EMA panel recommends Kaftrio for range of CF-causing mutations

A European Medicines Agency (EMA) committee recommended that the label for Kaftrio be expanded to cover treatment for people with cystic fibrosis (CF) caused by a wider array of mutations, Kaftrio’s developer Vertex Pharmaceuticals said. The Committee for Medicinal Products for Human Use (CHMP) opinion will be reviewed…

CF treatment Orkambi shows 2-year benefits in real-world study

Starting treatment with the CFTR modulator Orkambi (lumacaftor/ivacaftor) early in life may provide long-term benefits for children with cystic fibrosis (CF), yet lung function improvements may be temporary, according to a real-world study from Hungary. The study, “Body composition changes and clinical outcomes in pediatric cystic fibrosis…